News

“The whole is greater than the sum of its parts.” — Aristotle In today’s healthcare environment, an overwhelming percentage of resources are spent on treating diseases and their associated manifestations. While treatment of disease is an essential part of wellness, there is far more to being healthy than simply not being…

Differences in DNA may explain lung health and the risk of chronic obstructive pulmonary disease (COPD) in both smokers and non-smokers and could help in the future development of preventive and therapeutic strategies against COPD, a large-scale study reports. The study, “New genetic signals for lung function highlight pathways and…

Patients with chronic obstructive pulmonary disease (COPD) are unaware of their increased lung cancer risk compared with the general population — attributing their chest symptoms to factors other than potential cancer signs, according to a study. The researchers recommended campaigns to raise awareness about this risk since early lung cancer detection…

Nuvaira, a medical device company, announced it has secured $79 million to support the AIRFLOW-3 clinical trial to assess the company’s new targeted lung denervation (TLD) system, a minimally invasive treatment for chronic obstructive pulmonary disease (COPD). COPD includes a group of diseases characterized by chronic airway obstruction…

The first generic version of the inhalation treatment Advair Diskus (fluticasone/salmeterol powder) was recently approved by the U.S. Food and Drug Administration for chronic obstructive pulmonary disease (COPD) and asthma patients. According to a press release from developer Mylan, the therapy, called Wixela Inhub (fluticasone propionate and salmeterol inhalation powder),…